CSPC Pharmaceutical Group has been granted a patent for a pharmaceutical composition targeting Cx43 hemichannels in astrocytes or osteocytes to treat inflammatory or neurodegenerative diseases like spinal cord injury. The formulation includes specific antibodies and stabilizing agents within a defined pH range. GlobalData’s report on CSPC Pharmaceutical Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights CSPC Pharmaceutical Group Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on CSPC Pharmaceutical Group, Anti-bacterial thiazole derivatives was a key innovation area identified from patents. CSPC Pharmaceutical Group's grant share as of April 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.

Pharmaceutical formulation for treating inflammatory or neurodegenerative diseases

Source: United States Patent and Trademark Office (USPTO). Credit: CSPC Pharmaceutical Group Ltd

A recently granted patent (Publication Number: US11912764B2) discloses a pharmaceutical formulation designed to inhibit the opening of Cx43 hemichannels in cells. The formulation includes an anti-Cx43 antibody or antigen binding fragment, a buffer, a surfactant, and a stabilizer, with a pH range of 5 to 6. The antibody component comprises specific heavy and light chain complementarity determining region (CDR) sequences, with further variations in heavy chain variable domain sequences specified in the claims.

Moreover, the patent details the specific composition of the pharmaceutical formulation, including the concentration of the anti-Cx43 antibody, buffer selection (such as histidine/aspartic acid or histidine/histidine hydrochloride), the surfactant (polysorbate 80), and the stabilizer (sucrose). The pH range of the formulation is specified to be between 5.4 to 5.6, emphasizing its aqueous nature. The patent also outlines a method for administering the formulation to treat inflammatory or neurodegenerative diseases, highlighting its potential therapeutic applications in these conditions.

To know more about GlobalData’s detailed insights on CSPC Pharmaceutical Group, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies